Dergiler / Haseki Tıp Bülteni / 2021 / Cilt: 59 - Sayı: 5

Treatment Outcome and Mortality Among Geriatric Patients Diagnosed with Multiple-Drug Resistant Tuberculosis: A Comparative Analysis from a Tertiary Referral Center

Sayfa
377–380
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Nevertheless, we should be careful in terms of complications management of the geriatric population

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Multidrug-resistant (MDR) tuberculosis (TB) and drug-sensitive-TB have long treatment periods which affect patient compliance and treatment outcomes.
📊
Temel Bulgular & Veri:Methods: In a period of two years, a total of 82 elderly patients with bacteriologically proven TB enrolled into our retrospective study between 2011-2018.
💡
Sonuç & Katkı:Nevertheless, we should be careful in terms of complications management of the geriatric population
🔬Tür:Araştırma Makalesi
📍Kapsam:2011-2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Multidrug-resistant (MDR) tuberculosis (TB) and drug-sensitive-TB have long treatment periods which affect patient compliance and treatment outcomes. We planned to determine the factors that will affect the management of this disease in the elderly population. Methods: In a period of two years, a total of 82 elderly patients with bacteriologically proven TB enrolled into our retrospective study between 2011-2018. The patients’ demographic features, laboratory findings, and hospital records were analyzed. Results: We enrolled 67 (87.7%) patients with drug-sensitive TB and 15 (18.2%) MDR-TB in our study. In the study population, 73.2% (n=60) were male and the mean age was 75±9 years. When we compare treatment complications of MDR-TB and drug-sensitive-TB, we found out the rate of electrolyte imbalance, nephrotoxicity, and ocular toxicity more common among the MDR-TB group (p=0.008, p=0.008, and p=0.032, respectively). When we compare the mortality rate, cure, and treatment success between MDR-TB and drugsensitive TB, there were no statistically significant results (p=0.898, p=0.549, p=0.488; respectively). Conclusion: However, we think that this was due to the low sample size. Nevertheless, we should be careful in terms of complications management of the geriatric population

🔖

Bu Makaleye Atıf Yap

ILIAZ, S., ORTAKÖYLÜ, M. G., ONUR, S. T., ALKAN, F. (2022). Treatment Outcome and Mortality Among Geriatric Patients Diagnosed with Multiple-Drug Resistant Tuberculosis: A Comparative Analysis from a Tertiary Referral Center. Haseki Tıp Bülteni, Cilt: 59 - Sayı: 5, 377–380. https://ajindex.com/articles/535133

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Pratt RH, Winston CA, Kammerer JS, Armstrong LR. Tuberculosis in older adults in the United States, 1993-2008. J Am Geriatr Soc 2011;59:851-7
  2. Morris CD. Pulmonary tuberculosis in the elderly: a different disease? Thorax 1990;45:912-3
  3. Schaaf HS, Collins A, Bekker A, Davies PD. Tuberculosis at extremes of age. Respirology 2010;15:747-63
  4. Dousa KM, Kurz SG, Bark CM, Bonomo RA, Furin JJ. DrugResistant Tuberculosis: A Glance at Progress and Global Challenges. Infect Dis Clin North Am 2020;34:863-86
  5. World Health Organization Report. Global tuberculosis control 2017. Geneva: World Health Organization (WHO/HTM/ TB/2017.23); 2017. https://www.who.int/tb/publications/ global_report/gtbr2017_main_text.pdf (Accessed March 2019)
  6. Diel R, Rutz S, Castell S, Schaberg T. Tuberculosis: cost of illness in Germany. Eur Respir J 2012;40:143-51
  7. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012;40:9-11
  8. Natarajan A, Beena PM, Devnikar AV, Mali S. A systemic review on tuberculosis. Indian J Tuberc 2020;67:295-311
  9. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol 2020;128:1547-67
  10. Byng-Maddick R, Noursadeghi M. Does tuberculosis threaten our ageing populations? BMC Infect Dis 2016;16:119
  11. Yen YF, Feng JY, Pan SW, Chuang PH, Su VY, Su WJ. Determinants of mortality in elderly patients with tuberculosis: a populationbased follow-up study. Epidemiol Infect 2017;145:1374-81
  12. Ministry of Health and Welfare. Vital Statistics in Taiwan. Taiwan: Ministry of Health and Welfare, Executive Yuan. (http://www.mohw.gov.tw/CHT/DOS/ Statistic.aspx?f_list_ no=312&fod_list_no=1601). (Accessed December 2016
  13. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008;8:15
  14. Leung CC, Yew WW, Chan CK, et al. Tuberculosis in older people: a retrospective and comparative study from Hong Kong. J Am Geriatr Soc 2002;50:1219-26
  15. Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med 2007;167:1297-304
  16. Leung CC, Lam TH, Chan WM, et al. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol 2008;167:1486-94
  17. Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020